Positive Phase 2 Data on RDEA594, Ardea Biosciences' Lead Product Candidate for the Treatment of Hyperuricemia and Gout, Presented at the Annual European Congress of Rheumatology

PK/PD Study Interim Results

sUA Response - % of Patients

Treatment Groups

Allopurinol 300 mg

Alone

(n = 11)

RDEA594 400 mg

+ Allopurinol 300 mg

(n = 6)

RDEA594 600 mg

+ Allopurinol 300 mg

(n = 5)

< 6 mg/dL

27%

100%

100%

< 5 mg/dL

9%

67%

100%

< 4 mg/dL

0%

0%

60%